The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•18 March 2026•

1 min read

Vaxcyte Announces Publication of Positive Phase 1/2 Data for VAX-31 Vaccine in The Lancet

Key Facts

1The Lancet Infectious Diseases published positive Phase 1/2 data for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate.

Vaxcyte (PCVX) announced that the prestigious medical journal The Lancet Infectious Diseases has published positive results from its Phase 1/2 study of VAX-31. VAX-31 is a 31-valent pneumococcal conjugate vaccine candidate designed to provide broader protection against bacterial infections. Following these successful results, the company plans to advance the high-dose version of the vaccine into a comprehensive Phase 3 clinical program for adults. This peer-reviewed publication validates the vaccine's immunogenicity and safety profile, positioning it as a potential best-in-class competitor in the market. Investors are now looking toward the OPUS-1 pivotal trial, with topline data anticipated in the fourth quarter of 2026. The news reinforces Vaxcyte's clinical pipeline and reduces long-term development risks for its lead candidate.